Article

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma

2023-02-15

Abstract excerpt

<h4>Purpose: </h4> ： Chimeric antigen receptor (CAR)-T cells against CD19 have been proven to be effective in treating B-cell hematological malignancies. However, the efficacy of this promising therapy is limited by many factors. <h4>Methods: </h4>： In this study, the germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) cell line OCI-Ly1, and patient-derived xenografted (PDX) mice (CY-DLBCL) were...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 281c395d-0a21-582e-9bdb-7a11fc283fe2
DOI: 10.21203/rs.3.rs-2572328/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaDOI 10.21203/rs.3.rs-2572328/v1Read

Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLLSemantic proximity Read

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.Semantic proximity Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.Semantic proximity Read

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read

Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotypeSemantic proximity Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

Pomalidomide enhances CAR-T cell therapeutic efficacy and Remodels Immune Microenvironment in Lymphoid MalignanciesSemantic proximity Read

IL-7 promotes CD19-directed CAR-T cells proliferation through miRNA-98-5p by targeting CDKN1ASemantic proximity Read

Targeting autophagy overcomes cancer‐intrinsic resistance to CAR‐T immunotherapy in B‐cell malignanciesSemantic proximity Read